Lupin, Natco receives USFDA nod for Imatinib Mesylate tablets

Imatinib Mesylate is a generic version of Novartis Pharmaceuticals Corporation's Gleevec tablets in the same strengths, Lupin said in a filing to BSE.

New Delhi: Drug firm Lupin on Tuesday said it in alliance with Natco Pharma has received nod from the US health regulator to market generic Imatinib Mesylate tablets used for treatment of certain types of cancer.

The product is a generic version of Novartis Pharmaceuticals Corporation's Gleevec tablets in the same strengths, Lupin said in a filing to BSE.

Also Read: Relief to Lupin: High court removes ban its diabetes drug Gluconorm P 30

Lupin and Natco Pharma have received final approval from the US Food and Drug Administration (USFDA) to market generic Imatinib Mesylate tablets, 100 mg and 400 mg, the filing said.

As per IQVIA MAT December 2018 data, Imatinib Mesylate tablets, 100 mg (base) and 400 mg (base), had annual sales of approximately USD 655 million in the US, Lupin said.

Also Read: Natco Pharma submits new drug application with USFDA for generic Ibrutinib tablets